Tokyo, Japan and Cambridge, UK, 11 January 2021 – Sosei Group Corporation (“the Company”; TSE: 4565), today announced its Chief Financial Officer, Chris Cargill, will present at the 39th Annual J.P. Morgan Healthcare Conference, which will take place virtually, on Thursday, 14 January 2021.

The presentation will begin at 10:00 a.m. Eastern Standard Time, and will be video broadcasted live in English to registered conference attendees via the Digital Conference Book. For non-attendees, an audio link to the Company’s virtual session presentation can be accessed here. Presentation slides will be made available through the investor section of the Company’s Home Page, www.soseiheptares.com.

– Ends –

About Sosei Heptares

We are an international biopharmaceutical group focused on the discovery and early development of new medicines originating from our proprietary GPCR-targeted StaR® technology and structure-based drug design platform capabilities. We are advancing a broad and deep pipeline of novel medicines across multiple therapeutic areas, including neurology, immunology, gastroenterology and inflammatory diseases.

We have established partnerships with some of the world’s leading pharmaceutical companies, including AbbVie, AstraZeneca, Biohaven, Genentech (Roche), GSK, Novartis, Pfizer and Takeda and additionally with multiple emerging technology companies. Sosei Heptares is headquartered in Tokyo, Japan with corporate and R&D facilities in Cambridge, UK.

“Sosei Heptares” is the corporate brand and trademark of Sosei Group Corporation, which is listed on the Tokyo Stock Exchange (ticker: 4565). Sosei, Heptares, the logo and StaR® are trademarks of Sosei Group companies.

For more information, please visit https://www.soseiheptares.com/

LinkedIn: @soseiheptaresco | Twitter: @soseiheptaresco | YouTube: @soseiheptaresco